Keep in touch

Sub-Licensees

 

Aurobindo

Sub-licences covering: tenofovir alafenamide (TAF), atazanavir (ATV), abacavir (ABC), emtricitabine (FTC), cobicistat (COBI), elvitegravir (EVG) and the Quad [a combination of tenofovir, FTC, COBI, and EVG].

In September 2014, Aurobindo, the MPP and Gilead Sciences signed a new sub-licensing agreement, which replaces the previous one signed in September 2011, allowing Aurobindo to manufacture the novel investigational medicines tenofovir alafenamide (TAF), as well as  emtricitabine (FTC), cobicistat (COBI), elvitegravir (EVG), and the Quad [a combination of TDF, FTC, COBI, and EVG]

In July 2014, the MPP, Aurobindo and Bristol-Myers Squibb signed a new sublicencing agreement allowing it to manufacture atazanavir (ATV).

In June 2013, the MPP signed a sublicensing agreement with Aurobindo allowing it to manufacture abacavir (ABC) for paediatric use. This sublicensing agreement has been amended in November 2014 following the announcement of the extension of the MPP-ViiV Healthcare licence agreement to 121 countries.

 

top

Cipla

Sub-licences covering: atazanavir (ATV), tenefovir alafenamide (TAF), cobicistat (COBI), emtricitabine (FTC), elvitegravir (EVG) and the Quad [a combination of tenofovir, FTC, COBI, and EVG], dolutegravir (DTG)

In November 2014, Cipla, the MPP and Bristol-Myers Squibb signed a sublicensing agreement related to the antiretroviral medicines atazanavir (ATV).

In September 2014, Cipla, the MPP and Gilead Sciences signed a new sub-licensing agreement allowing Cipla to manufacture the novel investigational medicines tenofovir alafenamide (TAF), cobicistat (COBI), emtricitabine (FTC), elvitegravir (EVG) and the Quad [a combination of tenofovir, FTC, COBI, and EVG].

In July 2014, the MPP and ViiV Healthcare signed a sublicensing agreement with Cipla allowing it to manufacture dolutegravir (DTG) for paediatrics and adults use.

 

Desano

Sub-licences covering: dolutegravir (DTG), tenofovir alafenamide (TAF), tenofovir disoproxil fumarate (TDF), emtricitabine (FTC), cobicistat (COBI) and atazanavir (ATV)

In November 2014, the MPP, Desano and ViiV Healthcare signed a sub-licensing agreement allowing Desano to manufacture dolutegravir (DTG) for adults and paediatrics use.

In September 2014, the MPP, Desano and Gilead Sciences signed a sub-licensing agreement allowing Desano to produce a generic version of tenofovir alafenamide (TAF) and also of  tenofovir disoproxil fumarate (TDF), emtricitabine (FTC) and cobicistat (COBI).

In May 2014, the MPP  and Bristol-Myers Squibb signed a sublicensing agreement with the active pharmaceutical ingredient manufacturer Desano allowing it to manufacture atazanavir (ATV).

top

Emcure

Sub-licences covering: dolutegravir (DTG), tenofovir alafenamide (TAF), emtricitabine (FTC), cobicistat (COBI), elvitegravir (EVG) and the Quad [a combination of tenofovir, FTC, COBI, and EVG], atazanavir (ATV)

In October 2014, the MPP, Emcure and ViiV Healthcare signed a sub-licensing agreement allowing Emcure to manufacture dolutegravir (DTG) for adults and paediatrics use.

In September 2014, Emcure, the MPP and Gilead Sciences signed a new sub-licensing agreement, which replaces the previous one signed in January 2012, allowing Emcure to manufacture the novel investigational medicines tenofovir alafenamide (TAF), as well as emtricitabine (FTC), cobicistat (COBI), elvitegravir (EVG), and the Quad.

In July 2014, the MPP and Bristol-Myers Squibb signed a new sublicensing and technology transfer agreement with Emcure allowing it to manufacture atazanavir (ATV).

top

HEC Pharm

Sub-licences covering: tenofovir alafenamide (TAF), tenofovir disoproxil fumarate (TDF), emtricitabine (FTC) and cobicistat (COBI).

In May 2015, HEC Pharma, the MPP and Gilead Sciences signed a sub-licensing agreement allowing HEC Pharma to manufacture and sell tenofovir alafenamide (TAF), tenofovir disoproxil fumarate (TDF), emtricitabine (FTC) and cobicistat (COBI).

top

Hetero Labs

Sub-licences covering: lopinavir/ritonavir (LPV/r), tenofovir alafenamide (TAF), dolutegravir (DTG), emtricitabine (FTC), cobicistat (COBI), elvitegravir (EVG) and the Quad [a combination of tenofovir, FTC, COBI, and EVG].

In May 2015, the MPP, AbbVie and Hetero Labs signed a sub-licensing agreement, allowing Hetero to manufacture paediatric formulations of  lopinavir and ritonavir (LPV/r) for paediatric use.

In September 2014, Hetero Labs, the MPP and Gilead Sciences signed a sub-licensing agreement, replacing the previous one signed in July 2012,  allowing Hetero Labs to manufacture the investigational medicines tenofovir alafenamide  (TAF), as well emtricitabine (FTC), cobicistat (COBI), elvitegravir (EVG), and the Quad.

In August 2014, Hetero Labs, the MPP and ViiV Healthcare signed a sub-licensing agreement allowing Hetero to manufacture a generic version of dolutegravir (DTG) for both paediatrics and adults use.

top

Huahai Pharmaceutical

Sub-licences covering: tenofovir alafenamide (TAF), tenofovir disoproxil fumarate (TDF), emtricitabine (FTC) and cobicistat (COBI).

In May 2015, Huahai Pharmaceutical, the MPP and Gilead Sciences signed a sub-licensing agreement allowing Huahai to manufacture and sell generic versions of tenofovir alafenamide (TAF), tenofovir disoproxil fumarate (TDF), emtricitabile (FTC) and cobicistat (COBI).

top

Laurus Labs

Sub-licences covering: tenofovir alafenamide (TAF), dolutegravir (DTG), tenofovir disoproxil fumarate (TDF), emtricitabine (FTC), cobicistat (COBI), elvitegravir (EVG), and the Quad [a combination of TDF, FTC, COBI, and EVG].

In September 2014, Laurus Labs, the MPP and Gilead Sciences signed a new sub-licensing agreement, replacing the previous one signed in September 2012, allowing Laurus Labs to manufacture the investigational medicines tenofovir alafenamide  (TAF), as well as tenofovir disoproxil fumarate (TDF), emtricitabine (FTC), cobicistat (COBI), elvitegravir (EVG), and the Quad.

In July 2014, the MPP and ViiV Healthcare signed a sub-licensing agreement with Laurus Labs allowing it to manufacture dolutegravir (DTG) for paediatrics and adults use.

top

Lupin

Sub-licences covering: dolutegravir (DTG)

In July 2015, the MPP announced a sub-licensing agreement with Lupin allowing it to manufacture dolutegravir (DTG) for both paediatrics and adults use.

Micro Labs

Sub-licence covering: dolutegravir (DTG)

In July 2014, the MPP and ViiV Healthcare signed a sublicensing agreement with Micro Labs allowing it to manufacture dolutegravir (DTG) for both adult and paediatric treatment.

top

Mylan

Sub-licence covering: dolutegravir (DTG)

In July 2014, the MPP and ViiV Healthcare signed a sublicensing agreement with Mylan allowing it to manufacture dolutegravir (DTG) for both adult and paediatric use.

top

Shasun Pharma Solutions

Sub-licences covering: tenofovir (TDF), emtricitabine (FTC), cobicistat (COBI), elvitegravir (EVG), and the Quad [a combination of TDF, FTC, COBI, and EVG].

On 25 February 2013, the MPP and Gilead Sciences signed a sublicensing agreement with active pharmaceutical ingredient manufacturer Shasun Pharma Solutions for  tenofovir (TDF), emtricitabine (FTC), cobicistat (COBI), elvitegravir (EVG), and the Quad [a combination of TDF, FTC, COBI, and EVG].

top

Shilpa Medicare

Sub-licences covering: tenofovir (TDF), emtricitabine (FTC), cobicistat (COBI), elvitegravir (EVG) and the Quad [a combination of tenofovir, FTC, COBI, and EVG].

In June 2013, the MPP, Shilpa Medicare and Gilead signed a sublicensing agreement allowing it to manufacture five key HIV medicines  licensed to the MPP by Gilead Sciences in July 2011.

top

Strides Arcolab

Sub-licences covering: dolutegravir (DTG)

In July 2015, the MPP announced a sub-licensing agreement with Strides Arcolab allowing it to manufacture dolutegravir (DTG) for both paediatrics and adults use.

This page is also available in: French, Spanish